Bangladesh Medical Device Market Entry: Nine-Step Roadmap

1. Key takeaways

In practice the route from product classification to a market authorisation certificate in Bangladesh runs through nine steps: classify the product; appoint the local authorised representative; prepare the English technical material and QMS evidence; complete the CFS attestation chain; prepare Annexure-3 and the submission dossier; step one, recipe approval, taking 3 to 4 months; assemble original CFS documents and original empty boxes and labels; step two, final registration, taking 30 to 40 days and 2 to 3 months in practice; then MRP fixation and import formalities. The official figure for the total cycle is 4 to 6 months. The realistic figure, including document preparation and embassy attestation, is 12 to 24 months.

• Nine steps, of which two are formal review stages with their own clocks.
• Embassy attestation is completed abroad and cannot be accelerated locally.
• Recipe approval convenes quarterly, so one missed sitting costs roughly three months.
• Originals and physical packaging are a distinct step, not an afterthought.
• A certificate is not yet a saleable product; price approval is a separate act.

2. Legal basis

Only the first step rests on a specific guideline provision. The remaining steps reflect registration practice, and the table marks each accordingly so that a reader can see where the guidelines speak and where the market does.

Cycle comparison. The official process time is 4 to 6 months. The actual cycle, including document preparation, embassy attestation and two review stages, is 12 to 24 months (practical estimate).

3. Expert insights

Insight one: what sets project length is not step six or step eight on its own, but the coupling between step four and step six. The embassy attestation in step four happens outside the country and its duration is not controllable. The review in step six convenes quarterly, so a missed sitting means three months. Neither can be compressed and the two must run in sequence, which is the structural origin of the 12 to 24 month figure. A plan that treats these as parallel activities is not an optimistic plan; it is a plan built on the wrong model of the process.

Insight two: step seven is routinely dropped from schedules, and it blocks step eight directly. The final review stage requires submission of the original CFS and of the original empty box and label as physical items. Many manufacturers file with PDFs only and discover at the final stage that physical items must be couriered to Bangladesh, which adds a round of logistics that nobody planned. The thirteenth article of this series deals with that step in detail. Placing it in the schedule as a task with a shipping date removes the surprise.

Insight three: holding the registration certificate does not establish the conditions for sale. The MRP fixation and the import intent approval in step nine are independent administrative permissions and do not follow automatically from the certificate. The nine steps form a single chain, and a gap at any one of them leaves the investment in the previous eight temporarily unrealisable. That is the practical meaning of the six powers held by the DGDA: the instrument that allows a product onto the shelf is issued after the instrument that allows it into the country, and neither substitutes for the other.

4. Practical recommendations

• Schedule backwards. Fix the target submission date for recipe approval against the quarterly committee calendar first, then work back to the embassy attestation deadline, then back again to the date the technical documentation must be complete.
• Do not promise a compressed completion date. The quarterly sittings and the embassy attestation cycle are outside the control of the manufacturer, the agent and the consultant alike.
• Manage the controllable part weekly and present the uncontrollable part as risk. Clients accept a risk register far more readily than they accept a missed date explained after the fact.
• Place the original CFS and the physical packaging in the logistics plan with a shipping date, an owner and a tracking reference, rather than listing them as documents to be gathered.
• Build the budget and the commercial launch plan on 12 to 24 months, and treat the official 4 to 6 months as a statement about the review stages alone.
• Add MRP fixation and import intent approval to the pre-launch plan as separate milestones, each with its own submission and its own waiting period.

5. Verification checklist

• □ Classification completed and the written opinion retained
• □ LAR agreement signed, with the LAR holding a DIL and a trade licence
• □ Technical material and QMS evidence complete, including Class D design certification where applicable
• □ CFS attestation chain started and scheduled backwards from the quarterly committee date
• □ Annexure-3 prepared in the format currently prescribed by the DGDA
• □ Original CFS and original empty boxes and labels included in the logistics plan
• □ MRP fixation and import intent approval included in the pre-launch plan
• □ Project schedule built on 12 to 24 months rather than on the official 4 to 6 months

Regulatory information verified as of 27 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across South Asia, including Bangladesh. Our team prepares dossiers to DGDA expectations, manages submissions and deficiency responses, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com